Phase 3 data in hand, advisory committee voted 3-9 against — FDA's Aug 22 PDUFA on amended filing is the only question that matters

Capricor is a clinical-stage company developing deramiocel, a cell therapy for Duchenne muscular dystrophy, which is not yet approved.

Deramiocel, a cell therapy for the fatal cardiac and muscle decline of Duchenne muscular dystrophy, cleared a randomized Phase 3 trial with statistically significant results, yet drew a CRL and a 3-9 advisory committee vote against effectiveness. Whether FDA accepts the amended filing and grants approval on August 22 is the sole binary; a second rejection would leave no validated path forward. The burn rate of roughly $40M per quarter gives fewer than two years of runway, compressing the timeline for any recovery if approval is denied.